We will employ state of the art technologies to identify predictors of treatment response. We will use flow cytometry to analyze signaling networks in patient tumors and link this information to the tumor genetics and clinical course of the patient. This information will allow us to predict which patients will respond to specific treatment modalities. Further, as novel therapies that target signaling pathways are becoming more prevalent in the clinic this will allow for the design of treatment approaches for individual patients based on the biology of their tumor. This should lead to more effective treatments for patients with MM.